Free triiodothyronine (fT3) is the biologically active form of thyroid hormone that directly regulates metabolic rate, mitochondrial function, and protein synthesis by binding nuclear thyroid receptors. Most circulating T3 comes not from direct thyroid secretion, but from peripheral deiodination of T4 in the liver and other tissues, making fT3 a sensitive marker of both thyroid function and metabolic adaptation. Swedish reference fT3 ranges typically from 3.5–6.5 pmol/L, though laboratory-specific ranges vary.
Analyzed in accredited Swedish clinical laboratories (ISO 15189). Used to support clinician-directed evaluation and monitoring. Not a stand-alone diagnosis.
Free T3 testing is not routine screening — it is typically ordered when TSH is abnormal or when standard thyroid panels leave clinical questions unanswered. The key situations where fT3 adds value include: confirming thyrotoxicosis when TSH is suppressed but free T4 is normal (“T3 toxicosis”), diagnosing thyroid storm in acute presentations, and evaluating nonthyroidal illness syndrome (a pattern where T3 drops as an adaptive metabolic response during systemic illness even though TSH and fT4 remain normal).
If you experience unexplained fatigue despite normal standard thyroid tests, or have suspected thyroid dysfunction that standard screening has not clearly defined, fT3 can clarify whether active thyroid hormone availability is truly adequate. Many Swedish vårdcentraler do not reflexively order fT3 — it is typically a second-line test, often ordered through private longevity services like Loovi when clinical context warrants.
Clarifies active thyroid hormone status. fT3 measures the hormone that directly drives metabolism and mitochondrial function, unlike TSH which is a pituitary feedback signal and not the active hormone itself.
Flags T3 toxicosis. Identifies cases where TSH is suppressed but fT3 is elevated while T4 remains normal — a pattern sometimes missed by standard panels.
Reveals adaptation to illness. Low fT3 with normal TSH and fT4 during chronic illness indicates adaptive metabolic downregulation, not true thyroid failure — a distinction that changes clinical interpretation.
Guides management of thyroid hormone therapy. In patients on levothyroxine (T4) replacement, fT3 tracks whether peripheral conversion is adequate or whether T3 supplementation might be needed.
Contextualizes TSH discordance. When TSH looks normal but fatigue and metabolic symptoms persist, fT3 helps determine if the problem is truly thyroid-driven or metabolic adaptation to stress or undernutrition.
The biologically active thyroid hormone. T3 is the hormone that cells actually “read” — it binds thyroid hormone receptors on the nuclear membrane and in mitochondria, triggering increased metabolic rate, heat production, protein synthesis, and cellular energy expenditure. T4 (thyroxine), by contrast, is largely a storage and transport form; the body must convert it to T3 for biological activity.
Made mostly in the liver, not the thyroid gland. Although the thyroid gland secretes some T3 directly, the majority of circulating T3 comes from peripheral deiodination — enzymatic removal of an iodine atom from T4, primarily by deiodinase enzymes in the liver, kidney, and other tissues. This means T3 levels reflect not just thyroid function but also the efficiency of T4-to-T3 conversion and the nutritional and metabolic status of the tissues doing that conversion. Factors like selenium deficiency, severe illness, calorie restriction, and emotional stress all impair deiodinase activity, causing T3 to drop — often as an adaptive mechanism to conserve energy during adversity.
Tightly bound to proteins in the blood. Only a tiny fraction of T3 circulating in the blood is “free” (unbound); the rest is bound to thyroid-binding globulin (TBG), transthyretin, and albumin. The free fraction is what matters biologically, because only free hormone can enter cells and activate receptors. This is why fT3 (and free T4) are more physiologically relevant than total T3, which includes bound and free forms.
Identifies hidden metabolic dysfunction. Low fT3 with normal TSH and fT4 during chronic stress, undernutrition, or illness indicates metabolic adaptation, but it also reflects impaired mitochondrial signaling and reduced energy availability — patterns that, if prolonged, erode resilience and accelerate aging phenotypes.
Detects thyrotoxic states missed by standard screening. T3 toxicosis (elevated fT3, suppressed TSH, normal fT4) can cause atrial fibrillation, bone loss, and wasting if undiagnosed. Standard TSH-based screening sometimes misses this pattern until symptoms are severe.
Contextualizes the T4-replacement paradox. Some patients on levothyroxine remain symptomatic because they convert T4 to T3 poorly — a problem only visible by measuring fT3. Without fT3 data, clinicians may incorrectly assume the patient is thyroid-replete when metabolic hormone availability is actually limiting.
Signals metabolic reserve in aging. fT3 naturally declines with age and chronic illness, but premature drops (especially in younger individuals) suggest either acute stressor exposure or tissue-level metabolic dysfunction worth investigating and addressing.
Standard Swedish reference (vårdcentralen): Typically 3.5–6.5 pmol/L, though ranges are laboratory-specific and may vary between 3.0–7.0 pmol/L depending on assay method. Values within this range are considered “normal” in standard care.
Loovi optimal (longevity): 4.5–6.0 pmol/L — the upper-middle range where metabolic signaling is robust and mitochondrial function is well-supported, without the metabolic strain of frank hyperthyroidism.
Adaptive low (nonthyroidal illness): 3.0–4.5 pmol/L during acute or chronic systemic illness, when fT3 is suppressed as a metabolic brake — this is physiologically expected and often requires no treatment, but prolonged suppression warrants investigation into the underlying stressor.
fT3 is most meaningful when interpreted alongside TSH and free T4. An isolated fT3 value outside reference range has limited interpretive power; pattern recognition across the three markers is what drives clinical clarity.
Low fT3 (below 3.5 pmol/L). Low fT3 typically signals either true primary hypothyroidism (when TSH is elevated), secondary hypothyroidism (when TSH is inappropriately normal or low despite low fT4 and fT3), or adaptive metabolic suppression during illness, calorie deficit, or severe stress. In the context of normal TSH and fT4, low fT3 reflects reduced peripheral conversion, often driven by nutritional deficiency (selenium, iron), chronic inflammation, or the body's intentional metabolic downshift during hardship. Symptoms may include fatigue, cold intolerance, sluggish metabolism, and reduced energy expenditure.
Optimal fT3 (4.5–6.0 pmol/L). This range supports robust metabolic rate, mitochondrial biogenesis, protein turnover, and thermal regulation without excessive sympathetic activation. Most healthy individuals function well in this zone. fT3 in this range paired with normal TSH and fT4 indicates intact thyroid axis and healthy peripheral conversion efficiency.
High fT3 (above 6.5 pmol/L). Elevated fT3 suggests either primary hyperthyroidism (Graves disease, toxic nodule, thyroiditis), secondary hyperthyroidism, or intentional thyroid hormone over-replacement in patients on levothyroxine or liothyronine. Symptoms include tachycardia, heat intolerance, anxiety, tremor, insomnia, and bone loss. Thyroid-binding globulin (SHBG) elevation, estrogen-based contraceptive use, and pregnancy can also raise total T3 and sometimes modestly elevate fT3 by increasing binding protein levels.
Factors that influence fT3. Acute illness, severe calorie restriction, beta-blockers (which slow T4-to-T3 conversion), selenium and iron deficiency, and high emotional or training stress all lower fT3 acutely. Pregnancy, estrogen-containing contraceptives, and elevated SHBG increase thyroid-binding proteins and can slightly raise measured fT3. Recent intense exercise may transiently lower T3 as a metabolic adaptation. Timing of blood draw relative to meals and medication is less critical for fT3 than for TSH, but collection should still follow standard fasting protocols for consistency.
Primary thyroid disease. Hashimoto’s thyroiditis, Graves disease, thyroid nodules, and post-thyroidectomy all directly alter thyroid hormone output and affect circulating fT3 levels. In autoimmune thyroiditis, antibodies progressively destroy thyroid tissue, reducing fT3 production. In Graves disease, thyroid-stimulating immunoglobulin drives thyroid hyperfunction and elevated fT3.
Peripheral conversion failure. Selenium deficiency, zinc deficiency, and iron deficiency all impair deiodinase enzyme function, limiting the liver and kidney’s ability to convert T4 to T3. This is a major source of low-T3 syndrome in chronically ill, malnourished, or restrictively eating populations.
Metabolic stress and adaptation. Severe calorie restriction, fasting, acute illness, and chronic emotional stress downregulate deiodinase expression as a survival mechanism, dropping fT3 to conserve energy. This is adaptive short-term but, if prolonged, signals metabolic reserve depletion.
Medications and hormone factors. Beta-blockers (propranolol, atenolol) reduce peripheral conversion efficiency. Estrogen-containing contraceptives and hormone replacement raise SHBG, increasing thyroid-hormone binding and sometimes modestly elevating fT3. Amiodarone, lithium, and interferon can impair thyroid hormone metabolism and secretion.
Age and metabolic aging. fT3 naturally declines with advancing age, partly due to reduced tissue deiodinase expression and partly due to accumulating metabolic stress and inflammation. This age-related decline contributes to the slowing of metabolism and reduced thermogenesis in older adults.
Ensure adequate micronutrient status. Selenium and iron are critical cofactors for deiodinase enzymes. Restoring selenium and iron to optimal ranges (if deficient) can restore peripheral T4-to-T3 conversion efficiency. Zinc also supports immune thyroid health and conversion. These are not supplements to dose aggressively; they are nutritional baselines to be replete in.
Stabilize metabolic stress and support energy availability. Chronic undereating, excessive training without adequate recovery, and prolonged psychological stress all suppress T3 as a metabolic brake. Restoring energy availability (adequate calories, carbohydrate, and sleep) allows deiodinase upregulation and fT3 recovery. This is often more powerful than any single intervention.
Optimize liver and kidney function. Since the liver is the primary site of T4-to-T3 conversion, supporting hepatic health through alcohol moderation, metabolic syndrome reversal, and infection control (chronic viral reactivation suppresses conversion) indirectly supports fT3 availability. Renal function also declines with age and metabolic disease, reducing conversion capacity in the kidney.
Pharmacologic considerations (guided by a clinician). In patients with true hypothyroidism on levothyroxine (T4) monotherapy who remain symptomatic despite normal TSH, adding a small dose of liothyronine (T3) can restore fT3 into the optimal range. This is not a standard first-line move, but it is justified when T4-only replacement fails to resolve symptoms and fT3 remains suboptimal.
The levers that move fT3 are often structural (micronutrient repletion, stress reduction, energy availability, thyroid hormone dosing) rather than supplemental. The right approach depends on the individual’s baseline thyroid status, conversion capacity, and metabolic context — exactly what a Loovi longevity doctor maps out in consultation.
fT3 is meaningless without TSH and free T4. A single fT3 value cannot distinguish primary thyroid disease from adaptive metabolic suppression, cannot identify conversion failure, and cannot guide treatment. Testing all three together — TSH, free T4, and fT3 — reveals the full story: whether the hypothalamic-pituitary-thyroid (HPT) axis is intact, whether the problem is thyroid gland failure or central dysregulation, and whether peripheral conversion is working efficiently.
Beyond the thyroid panel itself, fT3 is far more interpretable when paired with SHBG (which affects thyroid-hormone binding and fT3 stability), ferritin and iron status (cofactors for deiodinase), and cortisol (elevated cortisol suppresses T4-to-T3 conversion). fT3 also correlates with metabolic rate and energy availability, which is why it contextualizes HbA1c, fasting insulin, and inflammatory markers like hs-CRP.
Loovi’s 120+ biomarker annual panel gives you the full metabolic picture — thyroid markers, iron and nutrient status, cardiovascular and inflammatory context, and performance metrics — so that when your fT3 moves, you understand why. That’s why membership gives you unrushed consultations with a Loovi longevity doctor who interprets your full data at once, supported by 80+ drop-in clinics across Sweden, results in 3 days, and an evolving personalized plan. From 295 SEK/month.
This pattern suggests either reduced peripheral T4-to-T3 conversion (often due to selenium deficiency, iron deficiency, or metabolic stress) or secondary hypothyroidism with an inappropriately “normal” TSH (a subtle pituitary or hypothalamic problem). It can also reflect adaptive metabolic suppression during chronic illness or severe calorie restriction, where the body intentionally lowers T3 to conserve energy. The distinction matters: true conversion failure needs micronutrient repletion and stress reduction, while adaptive suppression needs investigation into the underlying stressor.
fT3 is not part of the standard Swedish vårdcentral thyroid panel. Most låkare will only reflex-order fT3 when TSH is clearly abnormal. If you want fT3 as part of routine metabolic screening — as Loovi does — you’ll need a private longevity service. Many private clinics in Sweden now include fT3 alongside TSH and fT4 in comprehensive thyroid panels.
If fT3 is low due to selenium deficiency, restoring selenium to replete levels typically raises fT3 noticeably within 2–4 weeks, since deiodinase enzyme synthesis responds to selenium availability relatively quickly. If fT3 is low due to calorie restriction or stress, fT3 can begin to recover within 1–2 weeks once energy availability is restored and cortisol normalizes. However, if fT3 is low due to true primary hypothyroidism, the primary lever is thyroid hormone replacement (levothyroxine), not supplementation — this requires months to optimize dose and achieve steady-state fT3 levels.
Yes. Some individuals over-convert T4 to T3 due to genetic or acquired differences in deiodinase expression, or are given a levothyroxine dose that is too high relative to their TSH target. Others are intentionally on combined T4/T3 therapy (levothyroxine + liothyronine) to restore fT3 levels if T4 monotherapy leaves them symptomatic. Elevated fT3 on T4 therapy can cause atrial fibrillation, anxiety, tremor, and bone loss — your Loovi doctor checks fT3 to ensure your dose is optimized for both symptom relief and safety.
Estrogen-based contraceptives increase SHBG production, which binds thyroid hormones more tightly. This increases total T3 and total T4 but can subtly elevate free T3 as well, since more hormone is in circulation overall. Some women on contraceptives report mood or energy changes related to this shift. Free T3 may be slightly higher on oral contraceptives than at baseline, but the effect is modest and usually clinically insignificant unless the baseline dose of levothyroxine was already high.
In acute thyroiditis (often post-viral or post-partum), the damaged thyroid leaks stored thyroid hormones into circulation, causing fT3 (and fT4) to spike acutely, TSH to drop, and the patient to experience transient hyperthyroid symptoms. As the inflammation resolves, hormone leakage stops and fT3 and fT4 normalize. In chronic autoimmune thyroiditis (Hashimoto’s), fT3 gradually declines over months to years as the thyroid gland atrophies and loses hormone-producing capacity.
The fT3 to reverse-T3 ratio is sometimes promoted in functional medicine as a marker of conversion efficiency, but the evidence is weak. Reverse T3 is the inactive form of T3 (made when the body shunts T4 metabolism toward inactivation rather than activation), and high reverse T3 can indicate conversion impairment. However, most clinical laboratories do not measure reverse T3 as a matter of routine, and no major thyroid societies (including ESC or Swedish Endocrine Society) recommend it for routine screening. Focus on the core three — TSH, fT4, fT3 — and on addressing the modifiable drivers of conversion failure (nutritional status, stress, metabolic health) rather than chasing a calculated ratio.
Acute intense training can transiently lower T3 and elevate reverse T3 as a metabolic adaptation — the body suppresses active thyroid hormone to conserve energy during heavy exertion. This is normal and reversible within 24–48 hours with adequate recovery and nutrition. For consistency, blood draws should be taken at least 48 hours after intense exercise, and routine testing should occur when training load is at baseline. If you’re investigating low fT3, ensure you’re not in an acute overtraining phase when the sample is drawn.
fT3 above 7.5–8.0 pmol/L in a non-pregnant adult signals hyperthyroidism or over-replacement on thyroid hormone therapy. This state increases metabolic rate, heart rate, and sympathetic tone acutely, but sustained elevations increase risk of atrial fibrillation, accelerate bone loss, and impair muscle protein synthesis. Very high fT3 (above 9 pmol/L) can signal thyroid storm — a medical emergency characterized by extreme tachycardia, fever, and altered mental status. If your fT3 is markedly elevated, coordinate with your clinician urgently to identify the cause and adjust thyroid hormone therapy or address the underlying thyroid pathology.
